tbuckley/cabot-search huggingface dataset:
Anemia in Hodgkin's Disease
Authors: P Lederlin, G Mayer, G Thibaut, O Guerci, F Georges
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
Journal: Nature Reviews Neurology (2015)

The role of MRI in the assessment of multiple sclerosis (MS) goes far beyond the diagnostic process. MRI techniques can be used as regular monitoring to help stage patients with MS and measure disease progression. MRI can also be used to measure lesion burden, thus providing useful information for the prediction of long-term disability. With the introduction of a new generation of immunomodulatory and/or immunosuppressive drugs for the treatment of MS, MRI also makes an important contribution to the monitoring of treatment, and can be used to determine baseline tissue damage and detect subsequent repair. This use of MRI can help predict treatment response and assess the efficacy and safety of new therapies. In the second part of the MAGNIMS (Magnetic Resonance Imaging in MS) network's guidelines on the use of MRI in MS, we focus on the implementation of this technique in prognostic and monitoring tasks. We present recommendations on how and when to use MRI for disease monitoring, and discuss some promising MRI approaches that may be introduced into clinical practice in the near future.
Next generation sequencing (NGS) to identify targetable recurring mutations and exceptional responders in relapsed and high-risk childhood and adolescent/young adult (AYA) malignancies.
Authors: Brian Turpin, Rebekah Karns, Mayur Sarangdhar, Brian D. Weiss, James I. Geller, Michael Absalon, Maureen Megan O'Brien, Rajaram Nagarajan, Christine L. Phillips, Lionel M. Chow, Mariko Dawn DeWire, Denise Adams, Karen Cristly Burns, Trent Ryan Hummel, Maryam Fouladi, Adrienne Marie Hammill, Jennifer Mangino, Joseph Gerald Pressey, Bruce Aronow, John Peter Perentesis
Journal: Journal of Clinical Oncology (2015)

11011 Background: NGS has been rapidly introduced into routine clinical care for select adult malignancies, and the National Cancer Institute genomic precision medicine initiatives (e.g. M-PACT, NCI-MATCH) seek to use genetic sequencing-based treatment to improve response rates in select adult populations. However, the applicability of this technology in pediatric and AYA tumors has yet to be established. Methods: In an IRB-approved retrospective analysis of focused exome sequencing of 190 relapsed and high risk pediatric and AYA malignancies, 67 hematologic malignancies, 38 sarcomas, 34 neuroblastomas, 21 CNS, 7 liver, 6 renal, and 17
Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis
Authors: Sebum Lee, Yulei Shang, Stephanie A. Redmond, Anatoly Urisman, Amy A. Tang, Kathy H. Li, Alma L. Burlingame, Ryan A. Pak, Ana Jovičić, Aaron D. Gitler, Jinhua Wang, Nathanael S. Gray, William W. Seeley, Teepu Siddique, Eileen H. Bigio, Virginia M.-Y. Lee, John Q. Trojanowski, Jonah R. Chan, Eric J. Huang
Journal: Neuron (2016)
The Difference in Cognition Consistency Between the Sciences and Humanities
Authors: Jianzhang Zhou
Journal: Genomics Proteomics & Bioinformatics (2003)

It is reasonable that the strict sciences represented by mathematics, physics and chemistry have nearly been a kind of substitutional belief of humans after"the Death of God".To conclude theoretically, the significant attraction or the extremely great power of science is, in a word, the validity of thinking and action.From the viewpoint of human action or practice, science is the only really effective means we have to deal with nature (the other) that speaks the language of power.Being a creature that maybe has no competitive advantage in biological sense except the brain, men could not live in the world without power, and the subjective human power represented and embodied in science can be considered as the only secret by which we could stand above all the other beings on the earth.Cognitively, science is the language that has the most conciseness and certainty of thinking among all the theoretical discourse of human that aim at seeking the truth.Any theoretical disputation or problem in scientific fields will be solved ultimately.In the face of the methodology program composed of rational logic (mathematical calculation) and experimental demonstration (experiment), the true or false of competitive scientific presentations will be judged immediately and unimpeachably.Contrarily, in the research fields of the humanities, the fact that there are various opinions on the very matter and no one could say the last word about which is right is an obvious and common theoretical phenomenon in the liberal arts represented by literature, history and philosophy.As said by A. N. Whitehead, a modern American philosopher, all Western philosophies are just endless reinterpretations of the original philosophy questions asked by Plato.Cognition inconsistency is only a transitory exception during certain developing stages to sciences, but it becomes a regular rule to the humanities.According to the Paradigm theory of Thomas Kuhn, a contemporary scientific philosopher who suggested this theory after studying the process of the history of sciences, this phenomenon means
Vulnerable populations: lessons learnt from the summer 2003 heat waves in Europe
Authors: G Brücker
Journal: Eurosurveillance (2005)

What lessons can be learnt from the exceptionally long and severe heatwave experienced in Europe in 2003? First, that these heatwaves can be responsible for a dramatic excess mortality: certainly more than 50 000 excess deaths for Europe in August 2003. The consequences of the heatwave were probably underestimated in many countries, at least those based on the first estimates. This excess mortality affects vulnerable groups, particularly those who are old or ill. Identification of risk factors is a priority if the necessary prevention actions are to be implemented.
Objective volumetric grading of postacne scarring
Authors: Tatyana A. Petukhova, Negar Foolad, Neha Prakash, Vivian Y. Shi, Victoria R. Sharon, Lyndsay O'Brecht, Ifrah A. Ali, Stephanie Feldstein, Justin Halls, Qinlu Wang, Chin-Shang Li, Raja K. Sivamani
Journal: Journal of the American Academy of Dermatology (2016)
Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma
Authors: Nikhil C. Munshi, Stephane Minvielle, Yu-Tzu Tai, Mariateresa Fulciniti, Mehmet K Samur, Paul G. Richardson, Michel Attal, Philippe Moreau, Florence Magrangeas, Kenneth C Anderson, Malek Faham, Herve Avet-Loiseau
Journal: Blood (2015)
Highly wear-resistant and biocompatible carbon nanocomposite coatings for dental implants
Authors: Oleksiy V. Penkov, Vladimir E. Pukha, Svetlana L. Starikova, Mahdi Khadem, Vadym V. Starikov, Maxim V. Maleev, Dae-Eun Kim
Journal: Biomaterials (2016)
DDW Reports 2003 Orlando: Capsule Endoscopy
Authors: T Rösch
Journal: Endoscopy (2003)

Capsule endoscopy (CE) has attracted enormous interest in recent years, and a large number of abstracts were devoted to CE in various fields, ranging from the original indication of suspected small-bowel bleeding (SSBB) to possible indications in Crohn’s disease (CD) and other small-bowel diseases. Outcome studies are only slowly beginning to appear, and the use of CE in clinical situations (abdominal pain, diarrhea) rather than in more or less well-defined diseases or ”disease suspicion” situations has yet to be analyzed properly. As in other areas, some groups thought their results were so important that abstracts were submitted to (and accepted by) both the American Gastroenterological Association (AGA) and the American Society for Gastrointestinal Endoscopy (ASGE).
FAM therapy for advanced gastric cancer: an ideal standard?
Authors: S A Cullinan, C G Moertel
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.6.887 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3891923 FAM therapy for advanced gastric cancer: an ideal standard? S A CullinanxS A CullinanSearch for articles by this author , C G MoertelxC G MoertelSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.6.887 First Page PDF © 1985 by American Society of Clinical Oncology
Point: TheValue of Predicting Life Expectancy in Men with Clinically Localized Prostate Cancer
Authors: Douglass B. Clayton, Donald A. Urban
Journal: Journal of the National Comprehensive Cancer Network (2007)

The prediction of life expectancy in prostate cancer screening and treatment is a controversial topic that evokes various opinions regarding its validity. The authors believe incorporating life expectancy prediction into the treatment algorithms for prostate cancer is important. Using a combination of clinical judgment and specific predictive tools, physicians can estimate the life expectancy of patients with prostate cancer. These estimates can then be used to help guide treatment discussion. Estimating life expectancy benefits older men in whom decisions regarding the best form of treatment may be difficult.
QOS-21A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS
Authors: Katrin Scheinemann, JoAnn Duckworth, Sheila Singh
Journal: Neuro-Oncology (2016)

BACKGROUND: CNS tumors are the most common solid tumors in childhood.Given the complexity and comorbidities multiple health care workers from different disciplines are involved in the care.METHOD: Since 2008 a multidisciplinary team under the leadership of the neurooncologist for the care of pediatric CNS tumor patients was futher developed and prospectivly more disciplines were added due to the needs of the patients.RESULTS: Since 2008 around 24 patients with a new diagnosis of a pediatric CNS tumor and 5 relapses/ progression were treated on a yearly basis.Patients initally seen in the emergency room were visited by the neurosurgeon and neurooncologists following the initial imaging.Immediate inpatient care around the time of surgery was shared between these two disciplines.Disclosure was performed by the neurosurgeon and neurooncologist together including a dedicated social worker, the radiation oncologist was also present in case radiation therapy was needed.All these patients have had the same primary nurse/ case manager taking care of them since diagnosis.Given the different aspects of care the following disciplines were also part of the team: neuroradiology, neuropsychology, endocrinology, neuroophthalmology, social work, child life, occupational therapy, physiotherapy, dietician, interlink nurse and clinical research associate -all disciplines with a dedicated professional.Patients and parents do appreciate this model of care.CONCLUSION: Pediatric CNS tumor patients require a multidisciplinary care team with a dedicated case manager and a dedicated leader for optimal care.Overall survival
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Authors: Calvin Q. Pan, Zhongping Duan, Erhei Dai, Shuqin Zhang, Guorong Han, Yuming Wang, Huaihong Zhang, Huaibin Zou, Baoshen Zhu, Wenjing Zhao, Hongxiu Jiang
Journal: New England Journal of Medicine (2016)

Few data are available regarding the use of tenofovir disoproxil fumarate (TDF) during pregnancy for the prevention of mother-to-child transmission of hepatitis B virus (HBV).
Is EUTOS Score Predictive Of Outcome In Patients With Early Chronic Phase Chronic Myeloid Leukemia Treated With Imatinib? Preliminary Data From The National Protocol Of The Chilean Cooperative Group Panda
Authors: Javier Zelada, Marisa Pia Aida Capurro, Bernardita Rojas, Lilian M Pilleux, Augusto Aspillaga, Marvila Intriago, Jeanette Rosas, Diego Graver, Soledad S. Undurraga
Journal: Blood (2013)
The Ubiquitin-like Protein FAT10 Stabilizes eEF1A1 Expression to Promote Tumor Proliferation in a Complex Manner
Authors: Xiuxia Liu, Leifeng Chen, Jin Ge, Chen Yan, Zixi Huang, Junwen Hu, Chongyu Wen, Ming Li, Da Huang, Yumin Qiu, Haibin Hao, Rongfa Yuan, Jun Lei, Xin Yu, Jianghua Shao
Journal: Cancer Research (2016)

Abstract Human HLA-F adjacent transcript 10 (FAT10) is the only ubiquitin-like protein that can directly target substrates for degradation by proteasomes, but it can also stabilize the expression of certain substrates by antagonizing ubiquitination, through mechanisms as yet uncharacterized. In this study, we show how FAT10 stabilizes the translation elongation factor eEF1A1, which contributes to cancer cell proliferation. FAT10 overexpression increased expression of eEF1A1, which was sufficient to promote proliferation of cancer cells. Mechanistic investigations revealed that FAT10 competed with ubiquitin (Ub) for binding to the same lysines on eEF1A1 to form either FAT10–eEF1A1 or Ub–eEF1A1 complexes, respectively, such that FAT10 overexpression decreased Ub–eEF1A1 levels and increased FAT10–eEF1A1 levels. Overall, our work establishes a novel mechanism through which FAT10 stabilizes its substrates, advancing understanding of the biological function of FAT10 and its role in cancer. Cancer Res; 76(16); 4897–907. ©2016 AACR.
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Authors: Torben Bjerregaard Larsen, Flemming Skjøth, Peter Brønnum Nielsen, Jette Nordstrøm Kjældgaard, Gregory Y H Lip
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation. <b>Design</b>&nbsp;Observational nationwide cohort study. <b>Setting</b>&nbsp;Three Danish nationwide databases, August 2011 to October 2015. <b>Participants</b>&nbsp;61 678 patients with non-valvular atrial fibrillation who were naïve to oral anticoagulants and had no previous indication for valvular atrial fibrillation or venous thromboembolism. The study population was distributed according to treatment type: warfarin (n=35 436, 57%), dabigatran 150 mg (n=12 701, 21%), rivaroxaban 20 mg (n=7192, 12%), and apixaban 5 mg (n=6349, 10%). <b>Main outcome measures</b>&nbsp;Effectiveness outcomes defined a priori were ischaemic stroke; a composite of ischaemic stroke or systemic embolism; death; and a composite of ischaemic stroke, systemic embolism, or death. Safety outcomes were any bleeding, intracranial bleeding, and major bleeding. <b>Results</b>&nbsp;When the analysis was restricted to ischaemic stroke, NOACs were not significantly different from warfarin. During one year follow-up, rivaroxaban was associated with lower annual rates of ischaemic stroke or systemic embolism (3.0% <i>v</i> 3.3%, respectively) compared with warfarin: hazard ratio 0.83 (95% confidence interval 0.69 to 0.99). The hazard ratios for dabigatran and apixaban (2.8% and 4.9% annually, respectively) were non-significant compared with warfarin. The annual risk of death was significantly lower with apixaban (5.2%) and dabigatran (2.7%) (0.65, 0.56 to 0.75 and 0.63, 0.48 to 0.82, respectively) compared with warfarin (8.5%), but not with rivaroxaban (7.7%). For the combined endpoint of any bleeding, annual rates for apixaban (3.3%) and dabigatran (2.4%) were significantly lower than for warfarin (5.0%) (0.62, 0.51 to 0.74). Warfarin and rivaroxaban had comparable annual bleeding rates (5.3%). <b>Conclusion</b>&nbsp;All NOACs seem to be safe and effective alternatives to warfarin in a routine care setting. No significant difference was found between NOACs and warfarin for ischaemic stroke. The risks of death, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran compared with warfarin.
Neurology in the psychiatry Boards
Authors: B D Snyder
Journal: American Journal of Psychiatry (1977)

On the basis of his experience as an examiner, the author discusses the problems encountered in assessing psychiatrists' abilities in clinical neurology for certification by the American Board of Psychiatry and Neurology. Hoping to stimulate discussion among trainees, training programs, and the Board, he outlines five paradigms designed to survey neurological knowledge and skill potentially needed by psychiatrists in various situations; these are reduced to specific topics on which Board candidates should be questioned. Relationships between training and examination expectations are discussed.
Review of<i>Merritt’s Neurology</i>, 13th ed
Authors: Michael J. Aminoff
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Phenylboronic Acid-Mediated Tumor Targeting of Chitosan Nanoparticles
Authors: Xin Wang, Huang Tang, Chongzhi Wang, Jialiang Zhang, Wei Wu, Xiqun Jiang
Journal: Theranostics (2016)

The phenylboronic acid-conjugated chitosan nanoparticles were prepared by particle surface modification.The size, zeta potential and morphology of the nanoparticles were characterized by dynamic light scattering, zeta potential measurement and transmission electron microscopy.The cellular uptake, tumor penetration, biodistribution and antitumor activity of the nanoparticles were evaluated by using monolayer cell model, 3-D multicellular spheroid model and H22 tumor-bearing mice.The incorporation of phenylboronic acid group into chitosan nanoparticles impart a surface charge-reversible characteristic to the nanoparticles.In vitro evaluation using 2-D and 3-D cell models showed that phenylboronic acid-decorated nanoparticles were more easily internalized by tumor cells compared to non-decorated chitosan nanoparticles, and could deliver more drug into tumor cells due to the active targeting effect of boronic acid group.Furthermore, the phenylboronic acid-decorated nanoparticles displayed a deeper penetration and persistent accumulation in the multicellular spheroids, resulting in better inhibition growth to multicellular spheroids than non-decorated nanoparticles.Tumor penetration, drug distribution and near infrared fluorescence imaging revealed that phenylboronic acid-decorated nanoparticles could penetrate deeper and accumulate more in tumor area than non-decorated ones.In vivo antitumor examination demonstrated that the phenylboronic acid-decorated nanoparticles have superior efficacy in restricting tumor growth and prolonging the survival time of tumor-bearing mice than free drug and drug-loaded chitosan nanoparticles.
Tissue-engineered autologous grafts for facial bone reconstruction
Authors: Sarindr Bhumiratana, Jonathan C. Bernhard, David M. Alfi, Keith Yeager, Ryan E. Eton, Jonathan Bova, Forum Shah, Jeffrey M. Gimble, Mandi J. Lopez, Sidney B. Eisig, Gordana Vunjak-Novakovic
Journal: Science Translational Medicine (2016)

Anatomically shaped living bone formed in a portable bioreactor using autologous cells and bone matrix repaired the facial ramus-condyle unit in pigs.
Relevant clinical end points in biphosphonate trials.
Authors: J R Berenson, P Major, G Hortabagyi
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.9.3204 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9738595 Relevant clinical end points in biphosphonate trials. J R BerensonxJ R BerensonSearch for articles by this author , P MajorxP MajorSearch for articles by this author , G HortabagyixG HortabagyiSearch for articles by this author https://doi.org/10.1200/JCO.1998.16.9.3204 PDF "Relevant clinical end points in biphosphonate trials.." Journal of Clinical Oncology, 16(9), pp. 3204–3205© 1998 by American Society of Clinical Oncology